The winners of the UK Trade and Investment (UKTI) Innovation Competition are Abcodia, Critical Pharmaceuticals, Nanomerics and PsiOxus Therapeutics.
The companies will receive £1,500 towards flights and accommodation, and a year’s free membership of the BioIndustry Association (BIA).
The UKTI Innovation Competition, open to life science SMEs in the UK, highlights excellence in groundbreaking technologies for a global audience.
As the world’s largest biotechnology event, attended by delegates from more than 65 countries, the BIO Convention represents a major opportunity for small UK companies to make contacts.
Abcodia (London) discovers and validates biomarkers for the early detection and screening of cancer. Critical Pharmaceuticals (Nottingham) is developing a pipeline of recombinant protein and peptide therapies, using patented drug delivery technologies. Nanomerics (London) is a speciality pharmaceutical company that uses patented nanotechnology to boost the performance of known drugs. PsiOxus Therapeutics (Oxfordshire) is developing novel therapies for cancer and other life-threatening diseases.
Gareth King, CEO of Critical Pharmaceuticals, said: “We have recently announced the results of a second clinical study on our intranasal growth hormone product demonstrating clinical proof of concept, and look forward to meeting with commercial partners at BIO 2013 to progress the product into phase 2/3 clinical development.”
“Nanomerics is delighted to be able to showcase to a global audience its Molecular Envelope Technology, which boosts the activity of drugs and gets them where they need to be,” explained Andreas Schatzlein, CEO of Nanomerics. “In a time of undiminished medical need and increasing economic pressure it is crucial that we make the most of the drug compounds that we already understand.”